Chloroarenes

Health Canada releases decisions on neonicotinoid pesticides for impact on aquatic insects

Retrieved on: 
Wednesday, March 31, 2021
Insecticides, Neonicotinoids, Chemical compounds, Chloroarenes, Thiazoles, Organic compounds, Clothianidin, Chemical substances, Beekeeping, Pesticide toxicity to bees, Thiamethoxam, Pest Management Regulatory Agency

OTTAWA, ON, March 31, 2021 /CNW/ -Today,following a special review that included broad public consultation and science-based assessments, Health Canada released its decisions on the risks to aquatic insects from two neonicotinoid pesticides: clothianidin and thiamethoxam .

Key Points: 
  • OTTAWA, ON, March 31, 2021 /CNW/ -Today,following a special review that included broad public consultation and science-based assessments, Health Canada released its decisions on the risks to aquatic insects from two neonicotinoid pesticides: clothianidin and thiamethoxam .
  • To protect aquatic insects, Health Canada will be updating the use of some uses of clothianidin and thiamethoxam, and introducing additional mitigation measures and restrictions on some of the uses that remain registered.
  • When used according to new mitigation measures, clothianidin and thiamethoxam will not pose additional risks to aquatic insects.
  • Health Canada's Pest Management Regulatory Agency is responsible for pesticide regulation in Canada.

Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10® Immunotherapy for In-Transit Melanoma Lesions

Retrieved on: 
Wednesday, March 31, 2021
Organic compounds, Aromatic compounds, Chemical compounds, Cancer, Melanoma, Chloroarenes, Rose bengal

The Melanoma Research article, entitled Treatment of in-transit melanoma metastases using intralesional PV-10, detailed the experience of investigators at Melanoma Institute Australia (MIA; formerly the Sydney Melanoma Unit) in Sydney, Australia who treated 48 patients from 2008 to 2016.

Key Points: 
  • The Melanoma Research article, entitled Treatment of in-transit melanoma metastases using intralesional PV-10, detailed the experience of investigators at Melanoma Institute Australia (MIA; formerly the Sydney Melanoma Unit) in Sydney, Australia who treated 48 patients from 2008 to 2016.
  • This is the third publication about single-agent PV-10 treatment of ITM lesions under Provectus EAP (which has treated about 200 patients to date) and the fifth publication overall.
  • Mel Res 2008 ; subscription required): 11 (out of 20) patients treated in the Phase 1 trial; 1 PV-10 treatment; 27% patient CR (54% ORR).
  • Cancer Council Australia, Clinical practice guidelines for the diagnosis and management of melanoma: Treatment of satellite and in-transit metastases (May 2018)

Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis

Retrieved on: 
Tuesday, March 30, 2021
Digestive diseases, Medical specialties, Gastroenterology, Chloroarenes, Antiemetics, Prolactin releasers, Gastroparesis, Metoclopramide, Diabetes, Orally disintegrating tablet

During the call, Laidlaw & Company may be asking several submitted questions to Dr. Sideridis and Dr. McCallum.

Key Points: 
  • During the call, Laidlaw & Company may be asking several submitted questions to Dr. Sideridis and Dr. McCallum.
  • Evoke is a specialty pharmaceutical company focused primarily on the commercialization and development of drugs to treat GI disorders and diseases.
  • The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
  • The gastric delay caused by gastroparesis can compromise absorption of orally administered medications.

NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazindol CR)

Retrieved on: 
Monday, March 29, 2021
Psychoactive drugs, Amphetamine, Stimulants, Chloroarenes, Sleep disorders, Imidazolines, Mazindol, Narcolepsy, Attention deficit hyperactivity disorder

3016852, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).

Key Points: 
  • 3016852, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).
  • "We are very pleased to have obtained the first patent covering our novel formulation of controlled-release mazindol as we advance the development of Quilience to treat narcolepsy and other potential sleep-wake disorders," said Alex Zwyer, Chief Executive Officer of NLS.
  • "Our application for a similar patent in Europe received notice of allowance in January, and our U.S. patent application is pending review.
  • The Company's lead product candidate, Quilience is a proprietary controlled-release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy.

Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan

Retrieved on: 
Tuesday, March 23, 2021
Orphan drugs, Chemical compounds, Organic compounds, Drugs, Chloroarenes, Ureas, Protein kinase inhibitors, Cyclopropanes, Lenvatinib, Merck & Co., Eisai, Thymic carcinoma

TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.

Key Points: 
  • TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.
  • This marks the first approval for LENVIMA for unresectable thymic carcinoma in Japan.
  • For unresectable thymic carcinoma, platinum-based first-line therapy is recommended.
  • In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.

Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology

Retrieved on: 
Monday, March 22, 2021
Drugs, Orphan drugs, Chloroarenes, Imidazoles, Tipifarnib, HRAS, Head and neck cancer

The paper, titled Tipifarnib in Head and Neck Squamous Cell Carcinoma with HRAS Mutations, was published online in the Journal of Clinical Oncology earlier today.

Key Points: 
  • The paper, titled Tipifarnib in Head and Neck Squamous Cell Carcinoma with HRAS Mutations, was published online in the Journal of Clinical Oncology earlier today.
  • These data also reinforce the relevance of genomic testing for HRAS mutations to identify patients who could potentially benefit from tipifarnib treatment.
  • "We are pleased to see our data from the Phase 2 RUN-HN trial of tipifarnib published in the Journal of Clinical Oncology for review by the broader clinical community, said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
  • In addition to HNSCC, tipifarnib has demonstrated encouraging clinical activity in multiple additional genetically defined tumor types.

Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder

Retrieved on: 
Monday, March 22, 2021
Tonix Pharmaceuticals, Psychoactive drugs, Chemical compounds, Seth Lederman, Chloroarenes, Organic compounds, Tianeptine, Selective serotonin reuptake inhibitor, Bioequivalence

Tonixs TNX-601 CR is a novel oral formulation which is being developed as a potential treatment for MDD, posttraumatic stress disorder, and neurocognitive dysfunction associated with corticosteroid use.

Key Points: 
  • Tonixs TNX-601 CR is a novel oral formulation which is being developed as a potential treatment for MDD, posttraumatic stress disorder, and neurocognitive dysfunction associated with corticosteroid use.
  • We are pleased with the results of the FDA meeting on developing TNX-601 CR for the treatment of MDD and we look forward to advancing its clinical development, said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals.
  • We believe that with respect to tianeptine, TNX-601 CR would meet the bioequivalence standard for daily dosing of these immediate release (IR) products.
  • Given tianetptines unique metabolic pathway, we believe that TNX-601 CR has a reduced risk of drug-drug interactions compared to SSRIs5.

VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines

Retrieved on: 
Monday, March 22, 2021
GABAA receptor positive allosteric modulators, Psychoactive drugs, Chloroarenes, Benzodiazepines, Chemical compounds, Lactams, Organic compounds, Anxiolytics, Benzodiazepine, Alprazolam, Diazepam, Lorazepam

PH94Bs MOA is, therefore, fundamentally differentiated from the MOA of benzodiazepines such as alprazolam, diazepam and lorazepam, which are direct GABA-A receptor positive modulators.

Key Points: 
  • PH94Bs MOA is, therefore, fundamentally differentiated from the MOA of benzodiazepines such as alprazolam, diazepam and lorazepam, which are direct GABA-A receptor positive modulators.
  • Among VistaGens core goals is for PH94B to displace these and other widely-used but highly-addictive benzodiazepines in the acute treatment paradigm for SAD and other anxiety disorders and phobias.
  • PH94B also has therapeutic potential in a wide range of additional anxiety disorders and phobias.
  • To help differentiate PH94Bs mechanism of action from that of benzodiazepines, VistaGen studied whether PH94B had positive modulatory effects on GABA receptors.

The Quinism Foundation Encourages Those Injured by Hydroxychloroquine and Related Quinoline Antimalarial Drugs to File Timely Claims for Government Compensation

Retrieved on: 
Friday, March 19, 2021
Chemical compounds, Quinolines, Chloroarenes, Organic compounds, Drugs, Quinism, Mefloquine, Hydroxychloroquine, Chloroquine, Emergency Use Authorization, Encephalopathy, Tafenoquine

[1] Hydroxychloroquine and chloroquine were subsequently approved by the U.S. Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA).

Key Points: 
  • [1] Hydroxychloroquine and chloroquine were subsequently approved by the U.S. Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA).
  • Dr. Nevin noted that more information on how to file a claim could be found at https://www.hrsa.gov/cicp/filing-benefits , or by visiting the website of The Quinism Foundation, at https://quinism.org .
  • The Quinism Foundation, founded in January 2018, in White River Junction, Vermont, promotes and supports education and research on quinism, the medical disorder caused by exposure to quinoline drugs, including tafenoquine, chloroquine, hydroxychloroquine, and mefloquine.
  • Neuropsychiatric Quinism: Chronic Encephalopathy Caused by Poisoning by Mefloquine and Related Quinoline Drugs.

AV-101: A New Generation of Investigational Medicines in Neuropsychiatry and Neurology Known as NMDA Glutamate Receptor Modulators - Global Emerging Insight and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 18, 2021
Pharmaceutical, Health, Clinical trials, Other Health, Branches of biology, Glutamate neurotransmitter), Glutamate, Neurotransmitters, NMDA receptor antagonists, Drugs, Chloroarenes, Antidepressants, 4-Chlorokynurenine, N-Methyl-D-aspartic acid, Glutamate receptor

The "AV-101 - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "AV-101 - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • AV-101 (4-Cl-KYN) belongs to a new generation of investigational medicines in neuropsychiatry and neurology known as NMDA (N-methyl-D-aspartate) glutamate receptor modulators.
  • "AV-101 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Major Depressive Disorder in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.